## Abstract Signaling network controlling ribosome synthesis and function by Katherine M. Hannan et al., pp 79–85.
Signaling to the ribosome in cancer—It is more than just mTORC1
✍ Scribed by Katherine M. Hannan; Elaine Sanij; Nadine Hein; Ross D. Hannan; Richard B. Pearson
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 585 KB
- Volume
- 63
- Category
- Article
- ISSN
- 1521-6543
- DOI
- 10.1002/iub.428
No coin nor oath required. For personal study only.
✦ Synopsis
It is becoming increasingly clear that dysregulation of protein synthesis contributes to a range of diseases characterized by tissue overgrowth. These include arterial stenosis, cardiac hypertrophy, hamartomas, and cancer. The central hub for the regulation of protein synthesis is the ribosome, where the key signaling pathways downstream of RAS, MYC, and phosphatidylinositol-3-kinase (PI3K) converge to confer exquisite, coordinated control of ribosome synthesis and function. Such cooperation ensures strict regulation of protein synthesis rates and cell growth. This review will focus on the role the PI3K/AKT/mammalian target of rapamycin complex 1 (mTORC1) pathway plays in regulating ribosome function during both health and disease, its interaction with the other key growth regulatory pathways activated by RAS and MYC, and the therapeutic potential for targeting this network.
📜 SIMILAR VOLUMES
## Abstract Central core disease (CCD) is an autosomal‐dominant congenital myopathy, with muscle weakness and malignant hyperthermia (MH) susceptibility. We identified two of nine Brazilian CCD families carrying two mutations in the __RYR1__ gene. The heterozygous parents were clinically asymptomat
## Abstract Mutations in __KRAS__ or __BRAF__ frequently manifest in constitutive activation of the MEK1/2‐ERK1/2 signalling pathway. The MEK1/2‐selective inhibitor, AZD6244 (ARRY‐142886), blocks ERK1/2 activation and is currently undergoing clinical evaluation. Tumour cells can vary markedly in th